Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2013

View Archived Issues

Radioimmunotherapy proves safe in metastatic pancreatic cancer patients

Idiotype-based vaccine induces immune response against neuroblastoma

PD-0332991 shows single-agent activity in heavily pretreated patients with breast cancer

MK-1775 with carboplatin and paclitaxel passes interim analysis in ovarian cancer study

Researchers from AbbVie and Genentech present phase I data for ABT-199

Xoma presents preclinical results for novel IR allosteric monoclonal antibodies

Amgen and Servier collaborate on cardiovascular disease

Gilead Sciences presents new antiviral agents

Novartis patents novel Bcl-2 inhibitors for cancer

Italian group divulges novel lactate dehydrogenase inhibitors for cancer

Galapagos prepares new GPR84 receptor agonists

Researchers at Convergence Pharmaceutical disclose novel Na(v)1.7 channel blockers

New York State Department of Health approves MDxHealth's prostate cancer test

Austrian funding awarded to APEPTICO

Roche halts phase III trial of aleglitazar following safety review

Janssen announces approval of a high-dose HIV therapeutic

Pfizer obtains European approval to extend use of Prevenar 13 to adults aged 18 to 49 years

Trimel's NDA for intranasal gel testosterone product CompleoTRT accepted for review

ALK's allergy immunotherapy tablet beneficial in second pivotal trial

Abbott gains approval for next-generation XIENCE Xpedition stent in Japan

Breo Ellipta approved in Canada for chronic obstructive pulmonary disease

Phase II trial of squalamine eye drop reaches 50% enrollment

Biota Pharmaceuticals designs new topoisomerase IV inhibitors

hVps34 inhibitors prepared at Millennium Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...